AltrixBio present an abstract on LuCI™ at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) Conference.
Professor Jeffrey M Karp, Principal Investigator, Karp Lab (karplab.net), provides an overview of the current state of diabetes treatment.
We are delighted to share that AltrixBio has recently been featured in the August 2021 edition of Pharma Tech Outlook. Pharma Tech Outlook has named AltrixBio as one of the Top 10 Biotech Startups of 2021. The original article can be found…(BioMaterial)
Listen to Ali Tavakolli present “ATTD 2021 Tech Fair Grant Winner” LuCI™(BioMaterial)
The gastrointestinal tract is the site of most drug delivery and therapeutic interventions for the management and treatment of
numerous diseases. However, selective access to its mucosa, especially in the small bowel, is challenging.
An orally administered bifunctional gastrointestinal coating has been developed and shown to limit nutrient
absorption through the bowel mucosa ultimately lowering blood glucose and also acting as a platform for delivery
of drugs to the gastrointestinal tract.
The gastrointestinal tract is the major site of nutrient absorption in the body and plays a central role in the pathogenesis of many systemic diseases, including type 2 diabetes. The small intestine in particular has been recognized as an important therapeutic target to regulate sugar uptake into the blood.(BioMaterial)